

Direct Acting Antiviral Agents for Hepatitis C

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

All Antiviral Agents for Hepatitis C require prior authorization:

- The Plan's preferred Hepatitis C medications are included in **Table 1** below.
- The Plan requires that members be unable to use, or have tried and failed preferred medication(s) first.
- Requests for non-formulary and non-preferred hepatitis C medications will also be subject to the Plan's Non-Formulary Products Criteria (PG069).

Persons with hepatitis C virus (HCV) who are co-infected with hepatitis B virus (HBV) may be at risk for reactivation of HBV infection during or following HCV treatment. This includes those who are hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (HBsAb or anti-HBs) negative, but hepatitis B core antibody (HBcAb or anti-HBc) positive. Reactivation of hepatitis B can occur in someone who has a current HBV infection, or who has recovered from a past HBV infection – and can lead to rapid liver failure and death. Providers should test patients for HBV infection before starting HCV direct-acting antiviral (DAA) treatment. Providers should also monitor patients during and after hepatitis C treatment

for signs of HBV reactivation. HBV reactivation can be managed with appropriate use of antiviral treatment for HBV during HCV treatment with DAAs.

This policy references the most recent FDA prescribing information for each medication as well as guidelines and reports published by the American Association of the Study of Liver Diseases (AASLD) for consideration of approval of these medications. The FDA and AASLD set the patient selection and treatment considerations, choice of regimen, and duration of hepatitis C treatment. Please refer to the FDA website at <https://www.fda.gov/drugs> and AASLD website at www.hcvguidelines.org.

Table 1: Plan’s Preferred Direct Acting Antiviral Agents for Hepatitis C

Drug	FDA-Approved Indications
Epclusa (sofosbuvir/velpatasvir)	for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection. <ul style="list-style-type: none"> ● without cirrhosis or with compensated cirrhosis. ● with decompensated cirrhosis for use in combination with ribavirin.
Harvoni (ledipasvir/sofosbuvir)	Adults and pediatric patients 3 years of age and older with chronic HCV infection <ul style="list-style-type: none"> ● genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. ● genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin. ● genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin.
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)	Adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: <ul style="list-style-type: none"> ● genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. ● genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. <ul style="list-style-type: none"> ○ Additional benefit of sofosbuvir/velpatasvir/voxilaprevir (Vosevi) over sofosbuvir/velpatasvir (Epclusa) was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

Definitions

"**AASLD**" refers to the American Association of the Study of Liver Diseases, a professional medical society focused on liver diseases.

"**Compensated cirrhosis**" is a stage of liver cirrhosis classified as Child-Pugh Class A, indicating that the liver is still functioning adequately despite the presence of cirrhosis.

"**DAA**" are a class of medications used to treat hepatitis C. They specifically target key steps in the hepatitis C virus life cycle, reducing the viral load in the body. Most DAAs are used in combination therapy to enhance their effectiveness.

"**Decompensated cirrhosis**" is an advanced stage of liver cirrhosis classified as Child-Pugh Class B or C, indicating that the liver is no longer functioning properly and complications have arisen.

"**FDA**" refers to the Food and Drug Administration, a regulatory agency responsible for approving and monitoring the safety and efficacy of medications in the United States.

"**HBV**" refers to the hepatitis B virus, a viral infection that affects the liver.

"**HCV**" refers to the hepatitis C virus, a bloodborne virus that primarily infects the liver and can cause chronic liver disease.

"**IDSA**" refers to the Infectious Diseases Society of America, a professional medical society dedicated to preventing and treating infectious diseases.

"**NS5A inhibitor**" is a class of direct-acting antiviral medications used in the treatment of hepatitis C. Examples of NS5A inhibitors include elbasvir, ledipasvir, ombitasvir, and velpatasvir.

"**Resistance-associated substitutions (RASs)**" are genetic mutations in the hepatitis C virus that confer resistance to certain direct-acting antiviral medications. Examples include NS5A RASs, which can impact the effectiveness of regimens containing elbasvir/grazoprevir.

Medical Necessity Criteria for Initial Authorization

The Plan considers **Direct Acting Antiviral Agents for Hepatitis C** medically necessary when the following criteria are met:

1. The requested indication of use, patient selection, treatment consideration, and treatment duration is supported by **ONE** of the following:
 - a. FDA-approved indications and usage; **or**
 - b. The most current version of the AASLD/IDSA Clinical Practice Guideline, "*HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection*"; **AND**
2. The requesting prescriber has provided complete and up-to-date clinical documentation showing **ALL** of the following:
 - a. The requested medication is prescribed by a healthcare professional experienced in managing hepatitis C, including:
 - i. primary care providers for uncomplicated cases (e.g., compensated cirrhosis)
 - ii. specialists (hepatologist, gastroenterologist, liver transplant specialist, infectious disease specialist) in complicated cases (e.g., decompensated cirrhosis, co-infection with HIV, or other significant comorbidities); **and**
 - b. The member has a confirmed diagnosis of chronic hepatitis C; **and**
 - c. The member is within the appropriate age group for the requested medication based on FDA-labeled indication(s) or the most current AASLD/IDSA recommendations for testing, managing, and treating hepatitis C guidelines; **and**
 - d. Clinical chart documentation includes:
 - i. Detailed physical examination.
 - ii. Disease history.
 - iii. Viral load.
 - iv. Treatment history (including previous medications, start and stop dates, and outcomes of each prior treatment).
 - v. Treatment plan for HCV.
 - vi. Any concomitant conditions (such as HBV, HIV, or other coexistent liver and/or non-liver diseases).
 - vii. Specific considerations related to comorbidities such as type 2 diabetes mellitus, HIV, and renal impairment.
 - viii. Laboratory test results demonstrating hepatitis C viral load within 6 months prior to initiation of HCV treatment.

- ix. Laboratory results (i.e., biopsy and/or imaging study) demonstrating the presence or absence of cirrhosis (compensated or decompensated).
- x. The member has been assessed for potential nonadherence.

If the above prior authorization criteria are met, approval will be granted for one (1) treatment course for a duration based on FDA-labeled indication(s) or the most current AASLD/IDSA recommendations for testing, managing, and treating hepatitis C guidelines.

Medical Necessity Criteria for Reauthorization or Retreatment

Recommendations for retreatment of HCV in treatment-experienced individuals will be reviewed on a case-by-case basis, taking into consideration the following factors:

- Genotype and subtype, when applicable,
- Presence or absence of compensated cirrhosis,
- Prior regimen that was tried and failed,
- Presence or absence of viral variants harboring resistance-associated substitutions (RASs),
- Comorbidities, including type 2 diabetes mellitus, HIV, and renal impairment,
- Presence or absence of medication nonadherence.

Regimens for retreatment of HCV will be assessed based on FDA-labeled indication(s) or the most current AASLD/IDSA recommendations for testing, managing, and treating hepatitis C guidelines.

Experimental or Investigational / Not Medically Necessary

The safety and efficacy of Direct Acting Antiviral Agents for Hepatitis C for any indication not supported by FDA-labeled indication(s) or the most current AASLD/IDSA recommendations for testing, managing, and treating hepatitis C guidelines is considered not medically necessary by the Plan. Such indications are deemed to be experimental, investigational, or unproven.

References

1. Abraham GM, Obley AJ, Humphrey LL, Qaseem A; Scientific Medical Policy Committee of the American College of Physicians; Centor RM, Akl E, Forceia MA, Haeme R, Hamilton PG, Hood GA, Jokela JA, Kansagara DL, Levine MA, Mason JR, Marcucci M. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians. *Ann Intern Med.* 2021 Jan;174(1):98-100. doi: 10.7326/M19-3860. Epub 2020 Oct 6. PMID: 33017566.

2. American Association for the Study of Liver Diseases (AASLD) & Infectious Diseases Society of America (IDSA). (2021, January 21). HCV guidance: Retreatment of persons in whom prior therapy failed. Retrieved June 8, 2023, from <https://www.hcvguidelines.org/treatment-experienced>
3. American Association for the Study of Liver Diseases (AASLD) & Infectious Diseases Society of America (IDSA). (2021, September 29). HCV guidance: Initial treatment of adults with HCV infection. Retrieved June 8, 2023, from <https://www.hcvguidelines.org/treatment-naive>
4. American Association for the Study of Liver Diseases (AASLD) & Infectious Diseases Society of America (IDSA). (2021, September 29). HCV guidance: Patients with renal impairment. Retrieved June 8, 2023, from <https://www.hcvguidelines.org/unique-populations/renal-impairment>
5. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: <https://www.hcvguidelines.org/>. Accessed April 2022.
6. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. <https://www.hcvguidelines.org/>. Updated December 19, 2023.
7. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). HCV in children. <https://www.hcvguidelines.org/unique-populations/children>. Updated October 24, 2022.
8. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). HCV resistance primer. <https://www.hcvguidelines.org/evaluate/resistance>. Updated October 24, 2022.
9. Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis*. 2023 May 25;ciad319. doi: 10.1093/cid/ciad319. Epub ahead of print. PMID: 37229695.
10. Centers for Disease Control and Prevention (CDC). (2013). Testing for HCV infection: An update of guidance for clinicians and laboratorians. *MMWR Morbidity and Mortality Weekly Report*, 62(18), 362-365. PMID: 23677189
11. Centers for Disease Control and Prevention (CDC). (2020, August 7). Hepatitis C questions and answers for health professionals. Retrieved June 8, 2023, from <https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm>
12. Epclusa (sofosbuvir/velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2022.
13. Epclusa (sofosbuvir/velpatasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; June 2021.
14. European Association for the Study of the Liver (EASL), et al. (2018). EASL recommendations on treatment of hepatitis C 2018. *Journal of Hepatology*, 69(2), 461-511. PMID: 29481858
15. Ghany, M. G., et al. (2020). Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. *Hepatology*, 71(2), 686-721. PMID: 31899600
16. Harvoni (ledipasvir/sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2020.
17. Henderson DK, Dembry LM, Sifri CD, Palmore TN, Dellinger EP, Yokoe DS, Grady C, Heller T, Weber D, Del Rio C, Fishman NO, Deloney VM, Lundstrom T, Babcock HM. Management of healthcare personnel living with hepatitis B, hepatitis C, or human immunodeficiency virus in US

healthcare institutions. *Infect Control Hosp Epidemiol.* 2022 Feb;43(2):147-155. doi: 10.1017/ice.2020.458. Epub 2020 Oct 14. PMID: 33050959.

18. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. (2022). KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. *Kidney International*, 102(6S), S129-S205. PMID: 34954434
19. Sarrazin CP. Treatment Failure with DAA therapy: Importance of Resistance. *Journal of Hepatology*. March 2021. 74(6):P1472-1482. doi:https://doi.org/10.1016/j.jhep.2021.03.004
20. Sarrazin, C. P. (2021). Treatment failure with DAA therapy: Importance of resistance. *Journal of Hepatology*, 74(6), P1472-P1482. doi:https://doi.org/10.1016/j.jhep.2021.03.004
21. Vosevi (sofosbuvir, velpatasvir, voxilaprevir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2019.

Clinical Guideline Revision / History Information

Original Date: 11/05/2020

Reviewed/Revised: 06/24/2021, 12/01/2021, 06/23/2022, 06/29/2023, 09/18/2024